Tiazac XC · DIN 02256746 · 180 mg · extended release tablet
General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Tiazac XC · DIN 02256746
Manufacturer: Biovail Pharmaceuticals Canada; listing date 2005-05-25
Health Canada: Marketed since 2021-06-04 · brand TIAZAC XC · ATC C08DB01 DILTIAZEM · form Tablet (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 180 MG · company Bausch health, canada inc. · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02256746)
Source record
DIN 02256746: Tiazac XC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400162; group id 280; item number 0584; lccId None; manufacturer id BIO
Source form: ER Tab; strength: 180mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.4502; ministry $0.9195
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02256746
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74196
Interchangeable products
Teva-Diltiazem XC · DIN 02429322 · $0.9195
Shortage status: not checked (no credentials)